Recludix and Sanofi have established a strategic partnership to develop and commercialize first-in-class oral small molecule STAT6 (signal transducer and activator of transcription 6) inhibitors for patients with immunological and inflammatory diseases. STAT6 is believed to play a key role in multiple dermatological and respiratory diseases.
Recludix will advance the STAT6 inhibitor from preclinical development through the start of Phase 2 clinical trials. Sanofi is responsible for worldwide clinical development and commercialization thereafter. Recludix has an option to participate in an equal profit-sharing arrangement in the U.S., which includes certain co-promotion activities.
To learn more about the partnership, read the press release.
For inquires related to partnerships, email email@example.com.